Clinical trials are among the most expensive and consequential experiments in medicine. A misdesigned dose escalation scheme, an under-powered Phase II, or a missed drug interaction in a Phase III safety analysis can end a program. Computational pharmacology tools that support trial design and real-time safety monitoring have long been available — but typically only to organizations with dedicated pharmacometricians and clinical pharmacology teams. BioMate makes them accessible to every team entering the clinic.
Phase I: Dose Escalation Design
The primary objective of a Phase I first-in-human trial is to establish the maximum tolerated dose and identify the dose-limiting toxicities that will define the safety profile. The BOIN (Bayesian Optimal Interval) design is a model-assisted dose escalation method that adapts the escalation decision to accumulating safety data in a statistically principled way — producing better dose recommendations than rule-based 3+3 designs with the same or smaller patient numbers.
BioMate runs BOIN simulation, allowing clinical teams to evaluate the operating characteristics of a proposed escalation scheme — the probability of selecting each dose as the MTD, the expected trial duration, and the expected number of dose-limiting toxicities — before the trial opens. This simulation-based approach supports the justification regulators expect for the chosen design.
Population Pharmacokinetics
Population PK modeling characterizes the variability in drug exposure across patients — accounting for covariates like body weight, renal function, age, and genetic factors that alter how the drug is absorbed, distributed, metabolized, and eliminated. BioMate supports population PK analysis that can be used to rationalize dose adjustments for specific subgroups, understand the PK/PD relationship driving efficacy or safety, and support labeling decisions.
"Pharmacogenomics stratification — knowing which patients will have high or low exposure before they are enrolled — is one of the most powerful tools for improving both trial efficiency and patient safety."
Pharmacogenomics and Safety Signal Analysis
BioMate integrates pharmacogenomics (PGx) analysis for stratifying trial populations by genetic variants known to affect drug metabolism or response. For drugs metabolized by CYP2D6, CYP2C19, or other polymorphic enzymes, prospective PGx stratification reduces exposure variability and identifies subgroups at risk for adverse events before they are enrolled.
BioMate also supports pre-trial safety due diligence by querying FDA FAERS adverse event data for signals relevant to the drug class and mechanism, checking drug combination safety against known interaction databases. This contextualizes known class-level risks before the trial design is finalized.
Further reading: ClinicalTrials.gov (NIH), FDA clinical research guidance, BOIN dose-escalation design (Memorial Sloan Kettering), and Liu and Yuan 2015, BOIN design (PMC).
Trial design simulation, population PK analysis, PGx stratification, and safety signal monitoring no longer require a dedicated pharmacometrics team to access. BioMate makes these methods available to any clinical development team — with the documentation quality required for regulatory interactions built in.